The Learning Portal will be under maintenance 6-7 December. Portal functionality may be unavailable intermittently during this window.
We apologize for any inconvenience caused during this time.

  • Regulatory NewsRegulatory News

    European Regulatory Roundup: Commission Begins Investigation Into Cancer Drug Prices (18 May 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. European Commission Starts Formal Investigation into Aspen’s Cancer Drug Pricing The European Commission has opened a formal investigation into the way Aspen Pharma priced five cancer drugs. Officials began the probe after receiving reports indicating Aspen had imposed “very significant and unjustified price increases” on five off-patent cancer medicines it acquired ...
  • European Regulatory Roundup: Italy Fines Aspen $5.7M for Increasing Cancer Drug Prices by 1,500% (20 October 2016)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. Norwegian Government-Funded Study Supports Switching Patients to Remicade Biosimilar A trial funded by the Norwegian government has generated data to support switching from Johnson & Johnson’s Remicade to a biosimilar. Overall, participants with rheumatoid arthritis, Crohn’s disease and other conditions who switched to the biosimilar had comparable outcomes to patients ...